Form 4: Stryker VP Granted Equity Awards

Stryker's VP, Chief Accounting Officer, William E. Berry Jr., received grants of Restricted Stock Units and employee stock options.

Summary

• William E. Berry Jr., VP, Chief Accounting Officer of Stryker Corp (SYK), was granted 797 Restricted Stock Units (RSUs) and 2,391 employee stock options on February 4, 2026.
• The RSUs represent a contingent right to receive one share of Stryker Common Stock each and will vest in three equal installments on March 21, 2027, March 21, 2028, and March 21, 2029.
• The employee stock options have an exercise price of $360.82 and become exercisable as to 20% on each of the first five anniversaries of the grant date, expiring on February 3, 2036.
• Following these transactions, Mr. Berry directly beneficially owns 3,602 shares of Common Stock and 2,391 derivative securities (options), and indirectly owns 615 shares via his 401K.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management incentives with long-term shareholder value, without indicating any immediate operational changes.

Positives

• Grant of equity awards aligns management's interests with shareholders.
• Long-term vesting schedules for RSUs and options encourage sustained performance.

Negatives

• No immediate cash compensation or direct stock purchase, indicating a focus on future performance incentives.

Risks

• The value of the granted RSUs and stock options is tied to the future performance of Stryker's stock price, meaning their ultimate value could be lower than current market expectations if the stock price declines.
• Future stock price performance is subject to market conditions and company-specific factors.

Future Outlook

The equity grants are designed to incentivize long-term performance and retention of a key executive, aligning future compensation with the company's stock performance over several years.

Management Comments

• Represents a grant of Restricted Stock Units (RSUs) pursuant to the Stryker 2011 Long-Term Incentive Plan.
• Each RSU represents a contingent right to receive one share of Stryker Common Stock.
• Stock option granted pursuant to the Stryker Corporation 2011 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant.

Industry Context

StockSavvy.ai notes that equity grants, particularly RSUs and stock options with multi-year vesting schedules, are standard practice in the medical technology and healthcare industry to attract, retain, and motivate senior executives. This aligns executive incentives with long-term shareholder value creation, a common strategy among peers like Medtronic (MDT) and Johnson & Johnson (JNJ).

Comparison to Industry Standards

• The use of a combination of RSUs and stock options is a common compensation structure for executives in large-cap medical device companies, similar to practices at companies like Medtronic, where executives often receive a mix of performance-based equity and time-vesting awards.
• The multi-year vesting schedule (3 years for RSUs, 5 years for options) is consistent with industry benchmarks aimed at long-term retention and performance alignment, comparable to executive incentive plans at companies such as Abbott Laboratories (ABT) and Zimmer Biomet (ZBH).
• The grant of 797 RSUs and 2,391 options to a VP-level executive is within the typical range for such roles at a company of Stryker's size and market capitalization, reflecting competitive compensation practices.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive incentives with long-term stock performance.
• Employees: No direct impact on general employees, but reflects the company's approach to executive retention and motivation.

Next Steps

• Continued vesting of Restricted Stock Units on March 21, 2027, March 21, 2028, and March 21, 2029.
• Employee stock options will become exercisable annually over five years, starting February 4, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a corporate officer, which is a standard part of executive compensation. It does not contain information that would fundamentally alter the investment thesis for Stryker. The grants align executive incentives with long-term shareholder value, which is generally positive, but it's not a catalyst for a "buy" or "sell" recommendation. Therefore, a "hold" recommendation is appropriate as it maintains the current position based on existing fundamentals.

Keywords

Stryker, SYK, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation, William E. Berry Jr., Chief Accounting Officer